Bicycle Therapeutics plc

(NASDAQ:BCYC)

Latest On Bicycle Therapeutics plc (BCYC):

Date/Time Type Description Signal Details
2023-05-14 14:15 ESTNewsBicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs YetN/A
2023-05-10 11:38 ESTNewsBicycle stock jumps on pact with Bayer to develop radiopharmaceuticals for cancerN/A
2023-05-04 21:13 ESTNewsBicycle Therapeutics GAAP EPS of -$1.30, revenue of $4.89MN/A
2023-03-28 17:17 ESTNewsBicycle stock pops on cancer drug discovery pact with Novartis, gets $50M upfrontN/A
2023-02-28 15:09 ESTNewsBicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56MN/A
2023-02-14 18:15 ESTNewsBicycle Therapeutics posts Phase 1 data for cancer candidateN/A
2023-01-04 15:09 ESTNewsBicycle Therapeutics adds 10% on FDA’s fast track tag for bladder cancer therapyN/A
2022-11-03 21:35 ESTNewsBicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05, revenue of $3.04M misses by $2.54MN/A
2022-10-08 01:53 ESTNewsBicycle Therapeutics: Exploring An Intriguing Developmental PlatformN/A
2022-09-01 00:39 ESTNewsBicycle Therapeutics initiated Outperform at Cowen citing drug platformN/A
2022-08-04 22:13 ESTNewsBicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69MN/A
2022-07-12 21:29 ESTNewsBicycle to get $10M as Genentech uses option for new program under cancer drug collaborationN/A
2022-07-06 01:28 ESTNewsBicycle Therapeutics: Promising Early-Stage Cancer Drug DeveloperN/A
2022-05-05 19:05 ESTNewsBicycle Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $3.86M misses by $0.55MN/A
2022-04-17 04:20 ESTNewsBicycle Therapeutics: Trying To Catch This Falling KnifeN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer dataN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics presents at AACR Annual Meeting 2022 - SlideshowN/A
2022-04-09 02:28 ESTNewsBicycle Therapeutics gains on early-stage data for oncology asset in bladder cancerN/A
2022-03-27 00:04 ESTNewsBicycle Therapeutics: A Buy Ahead Of AACR PresentationN/A
2022-03-01 19:32 ESTNewsBicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11MN/A
2022-02-28 05:43 ESTNewsBicycle Therapeutics: An Oncology Play With Big PotentialN/A
2022-01-05 15:44 ESTNewsBicycle Therapeutics COO transitions to CTO; provides clinical program updatesN/A
2021-11-10 00:38 ESTNewsBicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is NextN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics gets dosing underway in early-stage BT7480 cancer trialN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics EPS beats by $0.03, misses on revenueN/A
2021-10-26 09:10 ESTNewsGenentech exercises option for new immuno-oncology program with Bicycle TherapeuticsN/A
2021-10-13 15:17 ESTNewsBicycle Therapeutics prices upsized ADS offering at $54N/A
2021-10-12 18:51 ESTNewsBicycle Therapeutics falls 5% on proposed ADS offeringN/A
2021-10-08 21:15 ESTNewsBicycle Therapeutics draws higher price targets from analysts after cancer study dataN/A
2021-10-08 01:35 ESTNewsBicycle's shares rise as early-stage candidate shows preliminary anti-tumor activity (updated)N/A
2021-08-25 11:00 ESTNewsBicycle Therapeutics: Scaffolding Short Linear Peptides Into BicyclesN/A
2021-08-05 20:10 ESTNewsBicycle Therapeutics EPS misses by $0.02, misses on revenueN/A
2021-07-22 16:37 ESTNewsIonis inks licensing deal with Bicycle Therapeutics to advance LICA technologyN/A
2021-05-07 01:50 ESTNewsBicycle Therapeutics EPS misses by $0.05, beats on revenueN/A
2021-03-18 11:26 ESTAnalyst RatingThe Analyst Target Price has increased from $34.88 to $36.75.Buy
2021-03-13 18:12 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$3.34 is estimated for the 2022 year.Sell
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 21:22 ESTNewsBicycle Therapeutics EPS misses by $0.32, beats on revenueN/A
2021-01-21 14:38 ESTAnalyst RatingThe Analyst Target Price has increased from $31.38 to $34.88.Buy
2021-01-18 06:16 ESTAnalyst RatingThe Analyst Target Price has increased from $27.75 to $31.38.Buy
2021-01-14 14:35 ESTNewsBicycle Therapeutics gives out pipeline update, shares riseN/A
2020-12-04 19:08 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 10:53 ESTAnalyst RatingThe Analyst Target Price has increased from $27.38 to $27.75.Buy
2020-12-02 13:28 ESTNewsBicycle Therapeutics settles IP dispute with PepscanN/A
2020-11-27 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 15:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $27.75 to $27.38.Neutral
2020-11-06 23:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 10:34 ESTEarnings EstimateAn EPS average of -$0.54 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-06 10:34 ESTAnalyst RatingThe Analyst Target Price has increased from $25.5 to $27.75.Buy

About Bicycle Therapeutics plc (BCYC):

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Quotes by TradingView

See Advanced Chart

General

  • Name Bicycle Therapeutics plc
  • Symbol BCYC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 87
  • Fiscal Year EndDecember
  • IPO Date2019-05-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.bicycletherapeutics.com
View More

Valuation

  • Trailing PE 1839
  • Price/Sales (Trailing 12 Mt.) 52
  • Price/Book (Most Recent Quarter) 6.83
  • Enterprise Value Revenue 51.14
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.92
  • Next Year EPS Estimate -$3.38
  • Next Quarter EPS Estimate -$0.60
  • Operating Margin -500%
  • Return on Assets -24%
  • Return on Equity -54%
  • Revenue 10.39 million
  • Earnings Per Share -$14.16
  • Revenue Per Share $0.54
  • Gross Profit -22759000
  • Quarterly Earnings Growth -27.1%
View More

Highlights

  • Market Capitalization 618.36 million
  • EBITDA -24381000
  • PE Ratio -6.18
  • Analyst Target Price $36.75
  • Book Value Per Share $5.33
View More

Share Statistics

  • Shares Outstanding 23.09 million
  • Shares Float 14.83 million
  • % Held by Insiders 2990%
  • % Held by Institutions 42.85%
  • Shares Short 400080
  • Shares Short Prior Month 397139
  • Short Ratio 2.76
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $33
  • 52 Week Low $10.5
  • 50 Day Moving Average 26.66
  • 200 Day Moving Average 21.57
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Bicycle Therapeutics plc (BCYC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Bicycle Therapeutics plc (BCYC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.83-$0.41-101.6%
2020-09-302020-11-05$N/A-$0.52-$0.531.89%
2020-06-302020-08-05$N/A-$0.67-$0.46-45.02%
2020-03-312020-05-07$N/A-$0.63-$0.38-64.36%
2019-12-312020-03-10$5.28 million-$0.25-$0.5251.62%
2019-09-302019-11-07$614000-$0.53-$0.7023.74%
2019-06-302019-08-08$1.52 million-$0.66-$0.62-6.45%
2019-03-312019-05-23$6.38 million-$0.49

Bicycle Therapeutics plc (BCYC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bicycle Therapeutics plc (BCYC) Chart:

Bicycle Therapeutics plc (BCYC) News:

Below you will find a list of latest news for Bicycle Therapeutics plc (BCYC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bicycle Therapeutics plc (BCYC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-11-2110CALL0 0700.42TRUE00
2025-11-2120CALL0 0457.5TRUE00
2025-11-2130CALL0 0331.78TRUE00
2025-11-2140CALL0 0246.37TRUE00
2025-11-2153.2CALL0 15180.78TRUE00
2025-11-2160CALL0 0181.91TRUE00
2025-11-2171.95CALL0 5684.56TRUE00
2025-11-2181.15CALL0 14127.95TRUE00
2025-11-2190.68CALL0 6387.99FALSE00
2025-11-21100.45CALL0 9216.08FALSE00
2025-11-21110.1CALL0 1816.85FALSE00
2025-11-21120CALL0 0839.42FALSE00
2025-11-21130CALL0 0859.56FALSE00
2025-11-21140CALL0 0877.71FALSE00
2025-11-2110PUT0 00FALSE00
2025-11-2120PUT0 0897.79FALSE00
2025-11-2130PUT0 0635.54FALSE00
2025-11-2140PUT0 0481.09FALSE00
2025-11-2150.05PUT0 30131.95FALSE00
2025-11-2160PUT0 0121.81FALSE00
2025-11-2170.1PUT1 12263.93FALSE0.10
2025-11-2180.5PUT40 2072.36FALSE00
2025-11-2191.3PUT0 2256.58TRUE00
2025-11-21100PUT0 0177.11TRUE00
2025-11-21110PUT0 00TRUE00
2025-11-21120PUT0 00TRUE00
2025-11-21130PUT0 00TRUE00
2025-11-21140PUT0 00TRUE00
2025-12-192.54.78CALL0 3247.48TRUE00
2025-12-1940CALL0 0169.27TRUE00
2025-12-1952.15CALL0 36133.91TRUE00
2025-12-1960CALL0 0176.81TRUE00
2025-12-197.50.6CALL0 68455.59TRUE00
2025-12-1991CALL0 1491.06FALSE00
2025-12-19100.7CALL0 275112.36FALSE00
2025-12-19110CALL0 0526.74FALSE00
2025-12-1912.50.4CALL0 19178.48FALSE00
2025-12-19150.2CALL0 97232.83FALSE00
2025-12-192.50PUT0 0481.86FALSE00
2025-12-1940PUT0 00FALSE00
2025-12-1950.1PUT0 28113.1FALSE00
2025-12-1960PUT0 0783.67FALSE00
2025-12-197.50.85PUT0 53151.96FALSE00
2025-12-1992.41PUT0 1167.03TRUE00
2025-12-19103.3PUT0 11116.04TRUE00
2025-12-19110PUT0 00TRUE00
2025-12-1912.50PUT0 00TRUE00
2025-12-19150PUT0 00TRUE00
2026-03-202.50CALL0 0140.69TRUE00
2026-03-2040CALL0 0127.99TRUE00
2026-03-2053.84CALL0 14166.02TRUE00
2026-03-2062.35CALL0 183.89TRUE00
2026-03-207.52.05CALL0 2265.09TRUE00
2026-03-2091.45CALL0 707204.03FALSE00
2026-03-20101CALL0 378373.93FALSE00
2026-03-20110.7CALL0 1308.57FALSE00
2026-03-2012.51CALL0 14184.14FALSE00
2026-03-20150.5CALL0 1016184.29FALSE00
2026-03-202.50PUT0 00FALSE00
2026-03-2040PUT0 0184.66FALSE00
2026-03-2050.35PUT0 5142.51FALSE00
2026-03-2060PUT0 0466.79FALSE00
2026-03-207.51.5PUT0 12319.1FALSE00
2026-03-2091.5PUT0 1233.28TRUE00
2026-03-20102.6PUT0 174.92TRUE00
2026-03-20110PUT0 070.6TRUE00
2026-03-2012.53.1PUT0 3075.49TRUE00
2026-03-20150PUT0 071.76TRUE00
2026-06-1810CALL0 0201.76TRUE00
2026-06-1820CALL0 0127.58TRUE00
2026-06-1830CALL0 0131.71TRUE00
2026-06-1840CALL0 0115.39TRUE00
2026-06-1854.55CALL0 990.09TRUE00
2026-06-1862.72CALL0 291.26TRUE00
2026-06-1870CALL0 087.87TRUE00
2026-06-1881.85CALL1 069.36TRUE1.850
2026-06-1891.6CALL0 2223.27FALSE00
2026-06-18101.55CALL0 79675.49FALSE00
2026-06-18111.15CALL0 2239.73FALSE00
2026-06-18120CALL0 0246.46FALSE00
2026-06-18130CALL0 0257.79FALSE00
2026-06-18140.5CALL0 2257.86FALSE00
2026-06-18150CALL0 0262.77FALSE00
2026-06-18160CALL0 0267.27FALSE00
2026-06-1810PUT0 0624.62FALSE00
2026-06-1820PUT0 00FALSE00
2026-06-1830PUT0 0321.48FALSE00
2026-06-1840PUT0 00FALSE00
2026-06-1850PUT0 0687.67FALSE00
2026-06-1860PUT0 0368.01FALSE00
2026-06-1870PUT0 1281.28FALSE00
2026-06-1880PUT0 1225.96FALSE00
2026-06-1891.85PUT0 179.95TRUE00
2026-06-18100PUT0 072.16TRUE00
2026-06-18110PUT0 071.96TRUE00
2026-06-18120PUT0 076.09TRUE00
2026-06-18130PUT0 072.16TRUE00
2026-06-18140PUT0 070.82TRUE00
2026-06-18150PUT0 076.33TRUE00
2026-06-18160PUT0 075.52TRUE00

Latest BCYC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST17$13.33
Jun 13, 2022 7:59 PM EST975$13.3
Jun 13, 2022 7:59 PM EST200$13.36

Bicycle Therapeutics plc (BCYC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-06-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1761612/000000000020005156/0000000000-20-005156-index.htm
2020-09-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000089914020000427/0000899140-20-000427-index.htm
2020-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000092963820000753/0000929638-20-000753-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1761612/000104746920002601/0001047469-20-002601-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060061/0001104659-19-060061-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060805/0001104659-19-060805-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/0001104659-19-062674-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919065673/0001104659-19-065673-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919075599/0001104659-19-075599-index.htm
2020-01-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920008696/0001104659-20-008696-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920010545/0001104659-20-010545-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920024459/0001104659-20-024459-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920027088/0001104659-20-027088-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920030969/0001104659-20-030969-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920031393/0001104659-20-031393-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920043974/0001104659-20-043974-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920057711/0001104659-20-057711-index.htm
2020-06-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1761612/000110465920070493/0001104659-20-070493-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1761612/000110465920072426/0001104659-20-072426-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-07-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920083108/0001104659-20-083108-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090550/0001104659-20-090550-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090870/0001104659-20-090870-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920110716/0001104659-20-110716-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1761612/000110465920111698/0001104659-20-111698-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920111705/0001104659-20-111705-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920121565/0001104659-20-121565-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051098/0001209191-19-051098-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051100/0001209191-19-051100-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051101/0001209191-19-051101-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119055217/0001209191-19-055217-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119061400/0001209191-19-061400-index.htm
2020-01-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001912/0001209191-20-001912-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001917/0001209191-20-001917-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001921/0001209191-20-001921-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001925/0001209191-20-001925-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001930/0001209191-20-001930-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001944/0001209191-20-001944-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001967/0001209191-20-001967-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001981/0001209191-20-001981-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001990/0001209191-20-001990-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002003/0001209191-20-002003-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002011/0001209191-20-002011-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002019/0001209191-20-002019-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120012510/0001209191-20-012510-index.htm
2020-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025811/0001209191-20-025811-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025812/0001209191-20-025812-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025813/0001209191-20-025813-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025816/0001209191-20-025816-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025817/0001209191-20-025817-index.htm
2020-08-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120047523/0001209191-20-047523-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120048252/0001209191-20-048252-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000138713120001831/0001387131-20-001831-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000138713120008376/0001387131-20-008376-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837019010277/0001558370-19-010277-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/0001558370-20-002278-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020005538/0001558370-20-005538-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020009277/0001558370-20-009277-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020012697/0001558370-20-012697-index.htm
2020-06-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1761612/999999999520001433/9999999995-20-001433-index.htm

Bicycle Therapeutics plc (BCYC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bicycle Therapeutics plc (BCYC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2990%
Institutional Ownership: 4285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-14Gregory Paul WinterDirectorBuy71,450.00163,927.00https://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm